Polyvalency: A promising strategy for drug design

Biotechnology and Bioengineering

Volumn 101, Issue 3, 2008, Pages 429-434

  Vance, David ^a   Shah, Mrinal ^a   Joshi, Amit ^a   Kane, Ravi S ^a  

^a Rensselaer Polytechnic Institute   (United States)

Author keywords

Anthrax toxin; Inhibitors; Ligands; Liposomes; Peptides; Polymers; Polyvalency

Indexed keywords

ANTHRAX TOXIN; INHIBITORS; LIPOSOMES; PEPTIDES; POLYMERS; POLYVALENCY;

LIGANDS;

DESIGN;

1,2 DISTEAROYLGLYCERO 3 PHOSPHOCHOLINE; ANTHRAX TOXIN; ANTHRAX TOXIN BINDING PEPTIDE; ANTITOXIN; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; LEUCYLTRYPTOPHYLPROLYLLEUCYLSERYLGLUTAMINYLLEUCYLASPARTYLHISTIDYLSERYLTYROSYLASP ARAGINE; LIPOSOME; PEPTIDE DERIVATIVE; POLYGLUTAMIC ACID; POLYVALENT ANTHRAX TOXIN INHIBITOR; PROPIONIC ACID DERIVATIVE; PYRIDYLTHIOPROPIONATE DERIVATIVE; UNCLASSIFIED DRUG;

CELL MEMBRANE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; IC 50; LIGAND BINDING; NONHUMAN; POLYVALENCY; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTIGENS, BACTERIAL; BACTERIAL TOXINS; DRUG DESIGN; MODELS, BIOLOGICAL; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53549095973     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22056     Document Type: Review

References (37)

1. Badjic JD, Nelson A, Cantrill SJ, Turnbull WB, Stoddart JF. 2005. Multi-valency and cooperativity in supramolecular chemistry. Acc Chem Res 38(9):723-732.
2. Basha S, Rai P, Poon V, Saraph A, Gujraty K, Go MY, Sadacharan S, Frost M, Mogridge J, Kane RS. 2006. Polyvalent inhibitors of anthrax toxin that target host receptors. Proc Natl Acad Sci USA 103(36):13509-13513.
3. Binder WH, Barragan V, Menger FM. 2003. Domains and rafts in lipid membranes. Angew Chem Int Ed 42(47):5802-5827.
4. Boder ET, Wittrup KD. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotech 15(6):553-557.
5. Brown DA, London E. 1998. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14:111-136.
6. Collier RJ, Young JAT. 2003. Anthrax toxin. Annu Rev Cell Dev Biol 19(1):45-70.
7. Cunningham K, Lacy DB, Mogridge J, Collier RJ. 2002. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc Natl Acad Sci USA 99(10):7049-7053.
8. Dixon TC, Meselson M, Guillemin J, Hanna PC. 1999. Anthrax. N Engl J Med 341(11):815-826.
9. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287):818-822.
10. Fan E, Zhang Z, Minke WE, Hou Z, Verlinde CLMJ, Hol WGJ. 2000. High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design. J Am Chem Soc 122(11):2663-2664.
11. Georgiou G, Stathopoulos C, Daugherty PS, Nayak AR, Iverson BL, Curtiss R III. 1997. Display of heterologous proteins on the surface of micro-organisms: From the screening of combinatorial libraries to live recombinant vaccines. Nat Biotech 15(1):29-34.
12. Golumbfskie AJ, Pande VS, Chakraborty AK. 1999. Simulation of biomi-metic recognition between polymers and surfaces. Proc Natl Acad Sci USA 96(21):11707-11712.
13. Gordon EJ, Sanders WJ, Kiessling LL. 1998. Synthetic ligands point to cell surface strategies. Nature 392(6671):30-31.
14. Joshi A, Saraph A, Poon V, Mogridge J, Kane RS. 2006. Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid. Bioconjug Chem 17(5):1265-1269.
15. Kane RS. 2006. Polyvalency: Recent developments and new opportunities for chemical engineers. AIChE J 52(11):3638-3644.
16. Kiessling LL, Gestwicki JE, Strong LE. 2006. Synthetic multivalent ligands as probes of signal transduction. Angew Chem Int Ed 45(15):2348-2368.
17. Kiick KI. 2007. Materials science: Polymer therapeutics. Science 317(5842): 1182-1183.
18. Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, Ling H, Pannu NS, Read RJ, Bundle DR. 2000. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403(6770):669-672.
19. Krishnamurthy VM, Estroff LA, Whitesides GM. 2006. Multivalency in ligand design. In: Jahnke DW, Erlanson DDA, editors. Fragment-based approaches in drug discovery. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. pp. 11-53.
20. Kulbachinskiy AV. 2007. Methods for selection of aptamers to protein targets. Biochemistry-Moscow 72(13):1505-1518.
21. Lewis JD, Destito G, Zijlstra A, Gonzalez MJ, Quigley JP, Manchester M, Stuhlmann H. 2006. Viral nanoparticles as tools for intravital vascular imaging. Nat Med 12(3):354-360.
22. Maheshwari G, Brown G, Lauffenburger DA, Wells A, Griffith LG. 2000. Cell adhesion and motility depend on nanoscale RGD clustering. J Cell Sci 113(10):1677-1686.
23. Mammen M, Choi S-K, Whitesides GM. 1998. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 37(20):2754-2794.
24. Mourez M, Kane RS, Mogridge J, Metallo S, Deschatelets P, Sellman BR, Whitesides GM, Collier RJ. 2001. Designing a polyvalent inhibitor of anthrax toxin. Nat Biotech 19(10):958-961.
25. Mulder A, Huskens J, Reinhoudt DN. 2004. Multivalency in supramolecular chemistry and nanofabrication. Org Biomol Chem 2(23):3409-3424.
26. Peppas NA. 1997. Hydrogels and drug delivery. Curr Opin Coll Interface Sci 2(5):531-537.
27. Pepper LR, Cho YK, Boder ET, Shusta EV. 2008. A decade of yeast surface display technology. Where are we now? Comb Chem High Throughput Screen 11(2):127-134.
28. Prausnitz MR, Mitragotri S, Langer R. 2004. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3(2):115-124.
29. Rai P, Padala C, Poon V, Saraph A, Basha S, Kate S, Tao K, Mogridge J, Kane RS. 2006. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat Biotech 24(5):582-586.
30. Rai PR, Saraph A, Ashton R, Poon V, Mogridge J, Kane RS. 2007. Raftlike polyvalent inhibitors of the anthrax toxin: Modulating inhibitory potency by formation of lipid microdomains. Angew Chem Int Ed 46(13):2207-2209.
31. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. 2006. Display technologies: Application for the discovery of drug and gene delivery agents. Adv Drug Del Rev 58(15):1622-1654.
32. Simons K, Ikonen E. 1997. Functional rafts in cell membranes. Nature 387(6633):569-572.
33. Srebnik S, Chakraborty AK, Shakhnovich EI. 1996. Adsorption-freezing transition for random heteropolymers near disordered 2D manifolds due to "Pattern Matching". Phys Rev Lett 77(15):3157.
34. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4(2):145-1160.
35. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968):505-510.
36. Veatch SL, Keller SL. 2003. Separation of liquid phases in giant vesicles of ternary mixtures of phospholipids and cholesterol. Biophys J 85(5): 3074-3083.
37. Zahnd C, Amstutz P, Pluckthun A. 2007. Ribosome display: Selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 4(3):269-279.